Literature DB >> 1694204

Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells.

V J Toothill1, J A Van Mourik, H K Niewenhuis, M J Metzelaar, J D Pearson.   

Abstract

We have characterized the mechanisms by which thrombin enhances neutrophil leukocyte (PMN) adhesion to human endothelial cells in vitro. Thrombin rapidly and transiently increased PMN adhesion by an action on the endothelial cells. The transience of the response was due to at least two factors: desensitization of the endothelial cell responsiveness to thrombin in the continued presence of the agonist; and the lability (t1/2 less than 15 min) of the effector molecules expressed by the endothelium. Experiments with exogenous platelet-activating factor (PAF) and with PAF antagonists demonstrated that PAF production, although it may facilitate the enhanced PMN adhesion seen in response to thrombin, is not sufficient to explain the reaction. By using a variety of antibodies directed against cell surface ligands, and comparing adhesion of PMN to endothelium and to protein-coated surfaces, we deduce that several endothelial ligands not previously reported as playing a role in PMN adhesion are involved in these interactions. Of particular interest was the finding that antibodies recognizing two thrombin-regulated endothelial cell surface ligands, GMP-140 and the CD63-related Ag, both inhibited adhesion of PMN to thrombin- or LPS-pretreated endothelium. We conclude that thrombin acts to enhance PMN adhesion to endothelium at least in part by transiently altering the conformation or level of expression of these ligands.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694204

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies.

Authors:  C O Savage; B E Pottinger; G Gaskin; C M Lockwood; C D Pusey; J D Pearson
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 2.  The endothelium: its role in scleroderma.

Authors:  J D Pearson
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

3.  Deficiency of the tetraspanin CD63 associated with kidney pathology but normal lysosomal function.

Authors:  Jenny Schröder; Renate Lüllmann-Rauch; Nina Himmerkus; Irina Pleines; Bernhard Nieswandt; Zane Orinska; Friedrich Koch-Nolte; Bernd Schröder; Markus Bleich; Paul Saftig
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 4.272

Review 4.  Tetraspanins and vascular functions.

Authors:  Feng Zhang; Jayaprakash Kotha; Lisa K Jennings; Xin A Zhang
Journal:  Cardiovasc Res       Date:  2009-02-27       Impact factor: 10.787

Review 5.  Will complex carbohydrate ligands of vascular selectins be the next generation of non-steroidal anti-inflammatory drugs?

Authors:  J L Winkelhake
Journal:  Glycoconj J       Date:  1991-10       Impact factor: 2.916

6.  Mechanisms of endothelial cell-dependent leukocyte adhesion stimulated by platelet-activating factor.

Authors:  Z Ding; S Li; Z Wu
Journal:  Inflammation       Date:  1992-04       Impact factor: 4.092

Review 7.  Selectins.

Authors:  M P Bevilacqua; R M Nelson
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

8.  Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins).

Authors:  F Berditchevski; M M Zutter; M E Hemler
Journal:  Mol Biol Cell       Date:  1996-02       Impact factor: 4.138

9.  Leukotriene B4-induced hyperadhesiveness of endothelial cells for neutrophils: relation to CD54.

Authors:  J E Palmblad; R Lerner
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

10.  Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells.

Authors:  W J Mayet; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.